Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. grew its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,159,854 shares of the life sciences company’s stock after acquiring an additional 72,294 shares during the quarter. Vanguard Group Inc. owned about 9.16% of Integra LifeSciences worth $273,435,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC increased its stake in Integra LifeSciences by 3.4% during the first quarter. Commonwealth Equity Services LLC now owns 7,916 shares of the life sciences company’s stock worth $454,000 after acquiring an additional 263 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Integra LifeSciences by 1.3% in the third quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company’s stock worth $802,000 after buying an additional 279 shares during the period. Inspire Investing LLC boosted its position in shares of Integra LifeSciences by 5.1% in the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock worth $306,000 after buying an additional 392 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of Integra LifeSciences by 0.3% in the third quarter. Public Employees Retirement System of Ohio now owns 128,880 shares of the life sciences company’s stock worth $5,459,000 after buying an additional 436 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its holdings in Integra LifeSciences by 0.3% in the second quarter. Segall Bryant & Hamill LLC now owns 175,465 shares of the life sciences company’s stock valued at $7,217,000 after purchasing an additional 463 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Up 1.8 %

IART opened at $35.45 on Friday. Integra LifeSciences Holdings Co. has a 12 month low of $33.24 and a 12 month high of $59.33. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The stock has a market cap of $2.79 billion, a P/E ratio of 42.71, a P/E/G ratio of 1.02 and a beta of 1.13. The stock’s 50 day moving average price is $39.49 and its 200 day moving average price is $39.70.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. During the same quarter in the prior year, the business earned $0.94 earnings per share. The firm’s revenue was down .3% compared to the same quarter last year. As a group, research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on IART shares. JMP Securities reduced their price target on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. Wells Fargo & Company raised Integra LifeSciences from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $40.00 to $49.00 in a report on Tuesday, December 5th. Truist Financial reduced their target price on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Finally, StockNews.com raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Thursday. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $45.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.